Stock Screener App

Frei -

Installieren

5.59

3.45% -0.20

Lenz Therapeutics Inc (LENZ)

Überblick Nachrichten Preisverlauf Forum Prognose

Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions - Yahoo Finance

Piper Sandler Maintains LENZ Therapeutics(LENZ.US) With Hold Rating, Maintains Target Price $12 - Moomoo

H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38 - Moomoo

LENZ Therapeutics Launches VIZZ Telehealth Prescribing Option for the Treatment of Presbyopia - VisionMonday.com

H.C. Wainwright reiterates Buy on LENZ Therapeutics stock on telehealth launch - Investing.com

LENZ Reiterates by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus

LENZ Therapeutics Inc (LENZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

LENZ Therapeutics, Inc. Launches New Telehealth Prescribing Option for VIZZ for the Treatment of Presbyopia - marketscreener.com

William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating - Moomoo

LENZ Therapeutics Launches Telehealth Access for VIZZ Alongside National TV Campaign - Quiver Quantitative

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ - LENZ Therapeutics

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia - Yahoo Finance

LENZLENZ Therapeutics Inc Options - Finviz

Director departure and audit committee change at LENZ Therapeutics (NASDAQ: LENZ) - Stock Titan

Price to book forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView

Price to sales forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView

Enterprise value to EBIT forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView

Enterprise value to revenue forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView

Price to earnings forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView

Enterprise value to EBITDA forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView

LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to Russell Microcap Value Benchmark Index - marketscreener.com

LENZ Therapeutics, Inc.(NasdaqGS: LENZ) added to Russell 2000 Value Benchmark - marketscreener.com

LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell 3000 Growth Benchmark - marketscreener.com

LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell 3000E Growth Benchmark - marketscreener.com

LENZ Therapeutics Surges 5.6%: Key Levels to WatchMomentum Stock Picks - dars.gov.et

LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Millennium Group reports 1.60M-share (5.1%) LENZ stake (LENZ) - Stock Titan

LENZ Therapeutics, Inc. Actuals & Estimates (NASDAQ:LENZ) - TradingView

LENZ Therapeutics, Arrotex Ink Commercialization Deal for VIZZ in Australia and New Zealand - VisionMonday.com

US prices for new drugs fell in 2025 as fewer costly gene therapies were launched - marketscreener.com

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst - Sahm

LENZ Therapeutics (LENZ) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ By Investing.com - Investing.com South Africa

LENZ Therapeutics signs exclusive VIZZ deal for Australia and New Zealand - grafa.com

LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ - Investing.com Australia

Lenz TherapeuticsArrotex Obtains Exclusive - Moomoo

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand - LENZ Therapeutics

LENZ Therapeutics, Inc. and Arrotex Pharmaceuticals Pty Ltd. Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand - marketscreener.com

LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

LENZ Therapeutics, Inc. (LENZ) reports Q1 loss, beats revenue estimates - MSN

LENZ Therapeutics Inc (LENZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

LENZ Therapeutics Inc (LENZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

LENZ Therapeutics Inc (LENZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

LENZ Therapeutics Inc (LENZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

LENZ Therapeutics Inc (LENZ) Institutional Confidence - TradingKey

LENZ Therapeutics Inc (LENZ) Valuation: PE, PB & Fair Value Analysis - TradingKey

LENZ Therapeutics Inc (LENZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

RA Capital-linked entities receive 22,100 LENZ (LENZ) options via director grant - Stock Titan

LENZ (LENZ) director receives 22,100 stock options at $6.63 strike price - Stock Titan

Director awarded 22,100 LENZ Therapeutics (LENZ) stock options - Stock Titan

Director-linked entities at LENZ Therapeutics (LENZ) granted 22,100 stock options - Stock Titan

LENZ Therapeutics Shareholders Back Board and Auditor Slate - The Globe and Mail

Lenz Therapeutics shareholders elect directors and ratify auditor at annual meeting By Investing.com - Investing.com South Africa

Lenz Therapeutics shareholders elect directors and ratify auditor at annual meeting - Investing.com Australia

[8-K] LENZ Therapeutics, Inc. Reports Material Event - Stock Titan

CCCC News | C4 THERAPEUTICS INC (NASDAQ:CCCC) - ChartMill

LENZ Technical Analysis & Stock Price Forecast - Intellectia AI

Everest medicines acquires greater china rights to aceclidine presbyopia eye drop (VIZZ) - Ophthalmology Times

Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ) - Ophthalmology Times

LENZ Therapeutics adds China partner for presbyopia drug VIZZ - Yahoo Finance

RPRX

$56.43

2.64%

INSM

$115.61

2.24%

ROIV

$35.97

2.28%

MRNA

$68.27

10.83%

ONC

$298.70

1.36%

RVMD

$186.88

2.22%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters